Agilent (A) Wants Pathology Labs To Go Digital, 540 Slides At A Time

On September 4, Agilent Technologies (NYSE: A ) launched a slide scanner in the United States that can hold up to 540 glass slides at once. The Agilent S540MD has FDA clearance and targets labs buried in samples and eyeing AI-assisted workflows. The launch is easy to overlook, but it arrives alongside a strong quarter, and that pairing is what makes it worth a look. Here's what the news adds to the story, and what it leaves open.

Start with the problem it solves. Pathology labs are handling more samples and feeling more pressure to turn out diagnoses faster, all while getting ready for AI-driven workflows. The S540MD is built for that volume. It takes up to 540 slides, can be refilled while it runs, and fits standard racks, so it slots into a lab's existing setup instead of forcing a rebuild. Automated scan modes and tissue detection take on more of the routine work. Majken Nielsen, who runs Agilent's Clinical Diagnostics Division, framed the scanner as a way to tie digitization to customers' staining workflows. And this isn't a cold start. The scanner reached select European markets in January, and it now sells in the United States alongside Germany, the UK, France, and a long list of other European countries.

On August 26, Agilent reported revenue of $1.88 billion for the quarter ended July 31, up 8.1% from a year earlier. Non-GAAP earnings per share rose 18%, a sign that sales growth is reaching the bottom line. CEO Padraig McDonnell credited better end markets, stronger regional demand and a warm response to new products, which is the kind of backdrop a fresh launch wants. Management then raised its full-year non-GAAP earnings guidance to $6.18 to $6.21 per share, showing it expects the strength to continue.

Now for the asterisks. The S540MD is really a rebadged Hamamatsu NanoZoomer S540MD, so the underlying hardware comes from someone else. Agilent's edge has to come from its pathology expertise and how neatly the scanner plugs into its staining workflows, which is harder to measure than a spec sheet. The announcement also offers no pricing, no unit targets, and no revenue estimate, so outsiders can't say how much this adds to the top line.

The quarter behind the launch has fine print of its own. Tariff refunds added $0.06 to non-GAAP earnings per share, and they also feed into the raised full-year outlook. The fourth-quarter guide assumes no more refunds. It also calls for core revenue growth of 5.2% to 6.2%, a step down from the 7.3% core pace in the third quarter.